TransGenic Group Inc - Company Profile
Powered by 
All the sales intelligence you need on TransGenic Group Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how TransGenic Group Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with TransGenic Group Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
TransGenic Group Inc (TransGenic) provides drug discovery support services, specializing in genetically modified animals and genome editing technologies like CRISPR/Cas9. Its services range from exploratory research to clinical trials, including gene function analysis, disease model production, antibody production, and protein synthesis. The company conducts non-clinical studies using both small and large animals for pharmaceuticals, medical devices, and food development. TransGenic supports clinical trials, including bioequivalence studies and pharmacokinetic measurements. It also offers advisory services in business succession, revitalization, and mergers & acquisitions (M&A), assisting with acquisition selection, financial due diligence, and restructuring. The company supports investment planning, funding strategies, and capital policy formulation. TransGenic is headquartered in Chuo-ku, Fukuoka, Japan.
Headquarters
Japan
Address
Ibbfukuoka Bldg., 2-3-36, Tenjin, Chuo-Ku, 810-0001
Website
transgenic-group.co.jp
Telephone
81 92 2888470
No of Employees
248
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2342 (TYO)
Revenue (2025)
$90.0M
-0.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-26767.7%
(2025 vs 2024)
Market Cap*
$28.9M
Net Profit Margin (2025)
XYZ
-28,033.3%
(2025 vs 2024)
* As of and is in US$
TransGenic Group Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Genetically Modified Mice | Drug Efficiency and Pharmacological Tests |
| Antibodies | Sugar Chain Analysis |
| Protein Hyper-Expressing Cells | Sugar Chain Synthesis |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In July, the company's subsidiary, BioSafety Research Center Inc, entered into an entrustment agreement with RevolKa Ltd for a non-clinical study using genetically modified animals to develop therapeutic agents for congenital rare diseases. |
| 2023 | Contracts/Agreements | In December, the subsidiary company Yasuhyo Center Co Ltd entered into a joint research and development agreement with Lead Pharma Co Ltd to develop nucleic acid drugs. |
| 2023 | Contracts/Agreements | In March, the company entered into a partnership agreement with Kurume Research Park to establish consolidated biopharmaceutical development network. |
Competitor Comparison
| Key Parameters | TransGenic Group Inc | Anhui Anke Biotechnology (Group) Co Ltd | Biocytogen Pharmaceuticals (Beijing) Co Ltd | Biocytogen Boston Corp | Central Institute for Experimental Medicine and Life Science |
|---|---|---|---|---|---|
| Headquarters | Japan | China | China | United States of America | Japan |
| City | Fukuoka | Hefei | Beijing | Waltham | Kawasaki |
| State/Province | Fukuoka | Anhui | Beijing | Massachusetts | Kanagawa |
| No. of Employees | 248 | 2,647 | 1,277 | - | - |
| Entity Type | Public | Public | Public | Private | Institution |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenji Fukunaga | Director; President; Chief Executive Officer | Executive Board | 2015 | 57 |
| Shunichi Kitajima | Director; Head-Facility Management Office; Head-CRO Business Division | Executive Board | 2018 | 66 |
| Kazuo Watanabe | Head-Accounting and Finance; Director | Executive Board | 2017 | 59 |
| Yutaka Funabashi | Director | Executive Board | - | 51 |
| Tsutomu Seito | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer